Quintrio
Home

Stock overview

Veraxa Biotech AG Ordinary Shares

VRXA

Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.

Last trade $1.03
Day change -$0.015 (-1.44%)
Day range $1.03 – $1.07
Volume 73,634
Market cap $148M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for VRXA.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for VRXA.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy

VERAXA Biotech announced its implementation of FDA-aligned New Approach Methodologies (NAMs) across its preclinical R&D programs to accelerate its BiTAC oncology pipeline while significantly reducing animal testing. The company presented data showing its BiTAC-TCE candidates demonstrated superior safety profiles and matched efficacy compared to traditional T cell engagers, with ex vivo studies using patient-derived xenograft models requiring only 10 mice versus 200+ for traditional studies.

GlobeNewswire Inc.

VERAXA Biotech Appoints Raju Willener as Chief Financial Officer

VERAXA Biotech AG announced the appointment of Raju Willener as Chief Financial Officer, effective immediately. Willener brings over 30 years of experience in global capital markets and biopharmaceutical finance. The appointment comes as VERAXA advances its BiTAC® platform and oncology pipeline toward clinical development.

GlobeNewswire Inc.

VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines

VERAXA Biotech announced substantial progress in its pipeline and partnering strategy, with plans to focus investments on its BiTAC platform for T cell engagers and antibody-drug conjugates. The company aims to have its lead BiTAC-TCE candidate VXA-102 IND/CTA-ready by early 2028 and intends to monetize non-BiTAC assets to finance growth. The company is actively pursuing partnerships and reported strong industry interest in its novel BiTAC technology.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.